Why Is STOKE THERAPEUTICS I (STOK) Stock Down Today?

Stoke Therapeutics stock closed down 5.33% at $23.97 on October 6 after opening with a modest 1.0% gap up. The sharp reversal came as the company announced two presentations of data for its investigational medicine STK-002 at the American Academy of Ophthalmology 2026 Annual Meeting. The stock fell to a session low of $23.96 shortly after the open and closed near that level. The move occurred despite recent positive developments, including the completion of a successful FDA meeting for its Dravet Syndrome candidate zorevunersen.

What Happened

Stoke Therapeutics announced that it will present data on STK-002, its investigational treatment for Autosomal Dominant Optic Atrophy, at the American Academy of Ophthalmology 2026 Annual Meeting. The company also confirmed it successfully met with the FDA to align on its planned U.S. New Drug Application for zorevunersen. Despite these developments, the stock declined sharply after opening higher. The session saw early optimism with a high of $25.73 at 9:30 AM ET, but the stock quickly reversed course and closed at $23.97. This marked a new 52-week low, with five such lows recorded on the same day.

What The Data Shows

The stock traded on 0.1 million shares, which is 0.1 times the 3-month daily average. The move came as insider selling continued, with six sales reported in the last 90 days totaling $899,000. The most recent insider transactions occurred on October 1 and October 2. The stock has a market capitalization of $1.7 billion, with a trailing twelve-month revenue decline of 86.2% and an unprofitable EPS of -3.33. The stock is currently trading within its 52-week range of $20.32 to $40.22.

What To Watch

Stoke Therapeutics has no upcoming earnings report listed. Investors will likely monitor the breadth of analyst coverage and any further updates from the AAO meeting or FDA process for zorevunersen.